HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

P P Tak Selected Research

TACI receptor-IgG Fc fragment fusion protein

11/2015Safety and efficacy of atacicept in combination with rituximab for reducing the signs and symptoms of rheumatoid arthritis: a phase II, randomized, double-blind, placebo-controlled pilot trial.
7/2011Atacicept in patients with rheumatoid arthritis and an inadequate response to tumor necrosis factor antagonist therapy: results of a phase II, randomized, placebo-controlled, dose-finding trial.
1/2008Atacicept in patients with rheumatoid arthritis: results of a multicenter, phase Ib, double-blind, placebo-controlled, dose-escalating, single- and repeated-dose study.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown:


P P Tak Research Topics

Disease

81Rheumatoid Arthritis
02/2018 - 02/2000
30Inflammation (Inflammations)
01/2017 - 01/2000
28Arthritis (Polyarthritis)
01/2017 - 01/2000
23Necrosis
09/2012 - 04/2003
12Experimental Arthritis
01/2017 - 01/2000
8Osteoarthritis
03/2006 - 03/2000
6Psoriatic Arthritis
01/2012 - 07/2004
5Autoimmune Diseases (Autoimmune Disease)
04/2014 - 04/2006
3Sjogren's Syndrome (Sjogren Syndrome)
04/2014 - 02/2006
3Rheumatic Diseases (Rheumatism)
01/2012 - 07/2005
3Fatigue
03/2010 - 06/2008
3Reactive Arthritis (Reiter Disease)
03/2006 - 03/2004
3Spondylarthropathies
05/2005 - 12/2002
3Joint Diseases (Joint Disease)
04/2005 - 03/2000
2Infections
02/2012 - 03/2007
2Arthralgia (Joint Pain)
03/2010 - 09/2008
2Atherosclerosis
09/2009 - 08/2009
2Pain (Aches)
08/2008 - 06/2008
2Multiple Sclerosis
10/2004 - 09/2004
1Hypersensitivity (Allergy)
11/2015
1Injection Site Reaction
11/2015
1Cardiovascular Diseases (Cardiovascular Disease)
09/2012
1Melanoma (Melanoma, Malignant)
06/2009
1Renal Cell Carcinoma (Grawitz Tumor)
06/2009

Drug/Important Bio-Agent (IBA)

21CytokinesIBA
01/2017 - 02/2000
16Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)IBA
04/2014 - 02/2000
14AntibodiesIBA
03/2015 - 03/2004
10Rituximab (Mabthera)FDA Link
11/2015 - 06/2008
9Adalimumab (Humira)FDA Link
09/2012 - 03/2009
9Methotrexate (Mexate)FDA LinkGeneric
02/2012 - 07/2000
8ChemokinesIBA
09/2011 - 09/2001
8Infliximab (Remicade)FDA Link
12/2010 - 07/2004
7Proteins (Proteins, Gene)FDA Link
01/2017 - 12/2001
6Biological ProductsIBA
01/2016 - 06/2006
6Antirheumatic Agents (DMARD)IBA
08/2013 - 07/2000
6Tumor Necrosis Factor InhibitorsIBA
02/2012 - 07/2007
5Rheumatoid FactorIBA
03/2014 - 05/2005
5Immunoglobulin M (IgM)IBA
03/2014 - 06/2009
5Interferon-betaIBA
06/2007 - 02/2000
4AutoantibodiesIBA
03/2014 - 09/2005
4Leflunomide (Arava)FDA LinkGeneric
02/2012 - 07/2000
4Matrix Metalloproteinases (MMPs)IBA
12/2011 - 09/2001
4InterleukinsIBA
06/2009 - 07/2003
4NF-kappa B (NF-kB)IBA
07/2007 - 08/2000
3TACI receptor-IgG Fc fragment fusion proteinIBA
11/2015 - 01/2008
3Peptides (Polypeptides)IBA
03/2015 - 01/2001
3Peptidoglycan (Murein)IBA
01/2015 - 03/2000
3Anti-Citrullinated Protein AntibodiesIBA
03/2014 - 09/2008
3Chemokine ReceptorsIBA
09/2011 - 10/2004
3Biomarkers (Surrogate Marker)IBA
08/2009 - 06/2005
3Interleukin-6 (Interleukin 6)IBA
12/2006 - 02/2000
3Granzymes (Granzyme)IBA
05/2005 - 01/2001
2flt3 ligand protein (flt3 ligand)IBA
01/2015 - 02/2014
2cyclic citrullinated peptideIBA
03/2014 - 09/2008
2GlucocorticoidsIBA
09/2012 - 10/2006
2Immunoglobulins (Immunoglobulin)IBA
05/2012 - 12/2010
2EpitopesIBA
03/2010 - 09/2008
2Interleukin-10 (Interleukin 10)IBA
08/2009 - 02/2006
2LipidsIBA
08/2009 - 04/2006
2Therapeutic UsesIBA
09/2008 - 09/2007
2Phosphatidylinositols (Phosphatidylinositol)IBA
07/2007 - 11/2006
2Reactive Oxygen Species (Oxygen Radicals)IBA
10/2006 - 07/2005
2InterferonsIBA
10/2006 - 03/2004
2beta-Galactosidase (Lactaid)IBA
02/2006 - 04/2005
2Monoclonal AntibodiesIBA
03/2005 - 02/2000
2Tissue Inhibitor of Metalloproteinase-1IBA
07/2003 - 02/2000
2Interleukin-1beta (Interleukin 1 beta)IBA
04/2003 - 02/2000
2DNA (Deoxyribonucleic Acid)IBA
08/2001 - 03/2000
2Metalloproteases (Metalloproteinases)IBA
08/2000 - 02/2000
1alpha7 Nicotinic Acetylcholine ReceptorIBA
01/2017
1GSK199IBA
01/2017
1EnzymesIBA
01/2017
1N- alpha- benzoyl- N5- (2- chloro- 1- iminoethyl)- L- ornithine amideIBA
01/2017
1Protein-Arginine DeiminasesIBA
01/2017
1Nicotinic Receptors (Nicotinic Acetylcholine Receptor)IBA
01/2017
1Protein-Arginine Deiminase Type 4IBA
01/2017
1Granulocyte-Macrophage Colony-Stimulating Factor Receptors (GM-CSF Receptor)IBA
10/2015
1CAM-3003IBA
10/2015
1Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF)IBA
10/2015
1Messenger RNA (mRNA)IBA
04/2014
1B-Cell Activating FactorIBA
04/2014
1Neutralizing AntibodiesIBA
04/2013
1AdipokinesIBA
09/2012
1ResistinIBA
09/2012
1ASK8007 monoclonal antibodyIBA
02/2012
1ocrelizumabIBA
02/2012
1OsteopontinIBA
02/2012
1Intercellular Adhesion Molecule-1 (Intercellular Adhesion Molecule 1)IBA
01/2012
1CX3C ChemokinesIBA
09/2011
1Fibroblast Growth Factors (Fibroblast Growth Factor)IBA
01/2010
1TWEAK ReceptorIBA
01/2010
1Immunomodulating AgentsIBA
09/2009
1Macrophage Migration-Inhibitory FactorsIBA
08/2009
1Etanercept (Enbrel)FDA Link
06/2009
1N 30IBA
06/2009
1Nuclear Antigens (Extractable Nuclear Antigens)IBA
06/2009

Therapy/Procedure

19Therapeutics
10/2015 - 01/2000
3Vagus Nerve Stimulation
02/2018 - 08/2014
2Biological Therapy
01/2016 - 07/2007
1Vagotomy
08/2014